Modality
Nanobody
MOA
SOS1i
Target
BTK
Pathway
Incretin
CTCL
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
Sep 2018
→ Feb 2029
Phase 3Current
NCT06093976
902 pts·CTCL
2019-05→2029-02·Recruiting
NCT08718315
2,527 pts·CTCL
2018-09→TBD·Completed
3,429 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-152.9y awayPh3 Readout· CTCL
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2029-02-15 · 2.9y away
CTCL
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06093976 | Phase 3 | CTCL | Recruiting | 902 | PANSS |
| NCT08718315 | Phase 3 | CTCL | Completed | 2527 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |